to see how well they work compared with sorafenib tosylate alone in treating patients with
locally advanced or metastatic liver cancer. Sorafenib tosylate may stop the growth of tumor
cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to
the tumor. Drugs used in chemotherapy, such as doxorubicin hydrochloride, work in different
ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
dividing. It is not yet known whether giving sorafenib tosylate together with doxorubicin
hydrochloride is more effective than sorafenib tosylate alone in treating liver cancer.
White River Junction, VT
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: firstname.lastname@example.org
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.